Septerna (NASDAQ:SEPN) Price Target Raised to $50.00 at Wells Fargo & Company

Septerna (NASDAQ:SEPN) had its price objective lifted by equities research analysts at Wells Fargo & Company from $48.00 to $50.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective indicates a potential upside of 4.69% from the company’s current price.

Several other research analysts have also recently issued reports on SEPN. Truist Financial lifted their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Stifel Nicolaus set a $49.00 price target on shares of Septerna in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. Guggenheim upped their price objective on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $49.00 target price on shares of Septerna in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.22.

Septerna Price Performance

Shares of NASDAQ:SEPN opened at $47.76 on Wednesday. The business has a fifty day moving average price of $34.94 and a 200-day moving average price of $29.25. The company has a market capitalization of $2.15 billion, a PE ratio of -88.44 and a beta of 2.29. Septerna has a 1-year low of $10.62 and a 1-year high of $48.00.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.59%. The company had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. On average, sell-side analysts anticipate that Septerna will post -1.59 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Daniel D. Long sold 15,000 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the completion of the sale, the senior vice president owned 96,412 shares in the company, valued at approximately $3,423,590.12. This represents a 13.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider directly owned 793 shares in the company, valued at approximately $23,837.58. This represents a 93.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 47,828 shares of company stock worth $1,584,314. Company insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently made changes to their positions in SEPN. First Light Asset Management LLC lifted its stake in shares of Septerna by 18.0% during the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after buying an additional 112,049 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Septerna during the first quarter valued at $619,000. Janus Henderson Group PLC bought a new stake in shares of Septerna in the 1st quarter worth about $21,334,000. Swiss National Bank bought a new stake in Septerna during the first quarter worth approximately $531,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Septerna in the 1st quarter worth approximately $906,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.